These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 28405473)

  • 21. Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.
    Yang Y; Li XF; Zhang X; Bao CD; Hu JK; Xu JH; Li XP; Xu J; He DY; Li ZJ; Wang GC; Wu HJ; Ji F; Zhan LJ; Zerbini CAF; Li ZG
    Rheumatol Ther; 2020 Dec; 7(4):851-866. PubMed ID: 32876903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1.
    Strand V; Mease PJ; Soriano ER; Kishimoto M; Salvarani C; Saffore CD; Zueger P; McDearmon-Blondell E; Kato K; Gladman DD
    Rheumatol Ther; 2021 Dec; 8(4):1789-1808. PubMed ID: 34636026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial.
    Strand V; Lee EB; Fleischmann R; Alten RE; Koncz T; Zwillich SH; Gruben D; Wilkinson B; Krishnaswami S; Wallenstein G
    RMD Open; 2016; 2(2):e000308. PubMed ID: 27752357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
    Kristensen LE; Soliman AM; Papp K; White D; Barcomb L; Lu W; Eldred A; Behrens F
    Rheumatology (Oxford); 2023 Feb; 62(2):629-637. PubMed ID: 35801915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Long-Term Treatment with Once-Daily Baricitinib 2 mg in Patients with Active Rheumatoid Arthritis: Post Hoc Analysis of Two 24-Week, Phase III, Randomized, Controlled Studies and One Long-Term Extension Study.
    Wells AF; Jia B; Xie L; Valenzuela GJ; Keystone EC; Li Z; Quebe AK; Griffing K; Otawa S; Haraoui B
    Rheumatol Ther; 2021 Jun; 8(2):987-1001. PubMed ID: 34028703
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2.
    Ostor AJK; Soliman AM; Papp KA; Padilla B; Wang Z; Eldred A; de Vlam K; Kivitz A
    RMD Open; 2022 Jun; 8(2):. PubMed ID: 35701011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
    Kremer JM; Schiff M; Muram D; Zhong J; Alam J; Genovese MC
    RMD Open; 2018; 4(1):e000581. PubMed ID: 29479473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
    Strand V; Burmester GR; Zerbini CA; Mebus CA; Zwillich SH; Gruben D; Wallenstein GV
    Arthritis Care Res (Hoboken); 2015 Apr; 67(4):475-83. PubMed ID: 25186034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baricitinib in Patients with Refractory Rheumatoid Arthritis.
    Genovese MC; Kremer J; Zamani O; Ludivico C; Krogulec M; Xie L; Beattie SD; Koch AE; Cardillo TE; Rooney TP; Macias WL; de Bono S; Schlichting DE; Smolen JS
    N Engl J Med; 2016 Mar; 374(13):1243-52. PubMed ID: 27028914
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study.
    Strand V; Rentz AM; Cifaldi MA; Chen N; Roy S; Revicki D
    J Rheumatol; 2012 Jan; 39(1):63-72. PubMed ID: 22045836
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of intravenous golimumab on health-related quality of life in rheumatoid arthritis: 24-week results of the phase III GO-FURTHER trial.
    Bingham CO; Weinblatt M; Han C; Gathany TA; Kim L; Lo KH; Baker D; Mendelsohn A; Westhovens R
    J Rheumatol; 2014 Jun; 41(6):1067-76. PubMed ID: 24786931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
    Genovese M; Westhovens R; Meuleners L; Van der Aa A; Harrison P; Tasset C; Kavanaugh A
    Arthritis Res Ther; 2018 Mar; 20(1):57. PubMed ID: 29566740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
    van der Heijde D; Dougados M; Chen YC; Greenwald M; Drescher E; Klar R; Xie L; de la Torre I; Rooney TP; Witt SL; Schlichting DE; de Bono S; Emery P
    RMD Open; 2018; 4(1):e000662. PubMed ID: 29765703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2.
    Strand V; Van den Bosch F; Ranza R; Leung YY; Drescher E; Zueger P; Saffore CD; Lertratanakul A; Lippe R; Nash P
    Rheumatol Ther; 2021 Dec; 8(4):1827-1844. PubMed ID: 34661885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.
    Wells AF; Greenwald M; Bradley JD; Alam J; Arora V; Kartman CE
    Rheumatol Ther; 2018 Jun; 5(1):43-55. PubMed ID: 29680881
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meaningful score changes for SF-36v2, FACIT-fatigue, and RASIQ in rheumatoid arthritis.
    Rendas-Baum R; Lin X; Kosinski M; Bjorner JB; Bracher MG; Chen WH
    J Patient Rep Outcomes; 2024 Jan; 8(1):9. PubMed ID: 38252223
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
    Taylor PC; Keystone EC; van der Heijde D; Weinblatt ME; Del Carmen Morales L; Reyes Gonzaga J; Yakushin S; Ishii T; Emoto K; Beattie S; Arora V; Gaich C; Rooney T; Schlichting D; Macias WL; de Bono S; Tanaka Y
    N Engl J Med; 2017 Feb; 376(7):652-662. PubMed ID: 28199814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib.
    Pope JE; Lee YC; Curtis JR; Mo D; Xie L; Dickson CL; Schlichting DE; Cardoso A; Simon LS; Taylor PC
    ACR Open Rheumatol; 2022 Mar; 4(3):254-258. PubMed ID: 34913611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.